Eikon Therapeutics
Business Services · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
3929 Point Eden Way, Hayward, California...Phone Number
(341) 777-0566Website
www.eikontx.comRevenue
$63.4 MillionIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
4
2
2
3
4
2
About Eikon Therapeutics
Eikon Therapeutics, founded in 2019, is a private biotechnology company headquartered in Hayward, California. Specializing in integrating advanced engineering with molecular and cell biology, Eikon aims to accelerate drug discovery and development.Explore more
Eikon Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eikon Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Eikon Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Eikon Therapeutics recently announced quarterly report
Click to see if Eikon Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Eikon Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Eikon Therapeutics launches new products
Check out if Eikon Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Eikon Therapeutics
Check if Eikon Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Eikon Therapeutics
Find 3 more new buyers
Compare Similar Companies to Eikon Therapeutics
Compare insights from companies similar to Eikon Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Eikon Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Eikon Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Eikon Therapeutics.
Eikon Therapeutics financials insights
Gather financial insights about Eikon Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$148M
2022
Series B
$517.8M
2023
Series C
$106M
2025
Series D
$351M
2026
IPO
$381.2M
Eikon Therapeutics Tech Stack
A closer look at the technologies used by Eikon Therapeutics
Most Recent Scoops
Project
Eikon Therapeutics has reported data at ASCO demonstrating that compound 1003 in combination with full-dose paclitaxel was tolerated at full dose intensity for both agents, with hematologic toxicity consistent with paclitaxel alone and no additive effect. The majority of patients, more than 90% of whom had received prior taxane therapy, responded or achieved stable disease, contrasting with prior failed attempts to combine olaparib with taxanes due to overlapping hematologic toxicity.
Medical Research
Project
Eikon Therapeutics is studying compound 1004, a brain-penetrant PARP-1 selective inhibitor designed to address CNS metastases in patients with BRCA-mutated breast cancer, with a large patient population exposed across multiple ascending dose escalation studies. Data from these studies, including monitoring of CNS-specific adverse effects such as mood changes, sensorium changes, and seizure disorders, are expected to be presented at ESMO in October.
Medical Research, Pharmaceuticals
Project
Eikon Therapeutics has developed EIK1005, an orally bioavailable Werner Helicase (WRN helicase) inhibitor with a half-life exceeding nine days, enabling once-weekly dosing, discovered using Eikon Therapeutics's super-resolution microscopy platform by screening for changes in WRN helicase motion characteristics. Due to its favorable preclinical profile, EIK1005 was initially studied in healthy volunteers prior to advancing to patient studies.
Pharmaceuticals
Project
Eikon Therapeutics has reported that its PARP-1 inhibitors, compounds 1003 and 1004, demonstrate 650 to 800-fold selectivity for PARP-1 over PARP-2 at the enzymatic level. Eikon Therapeutics's development strategy centers on demonstrating that this rigorous PARP-1 selectivity eliminates myelosuppressant hematologic toxicity, enabling improved patient persistence on therapy and upstream combination with chemotherapeutic agents.
Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals
Eikon Therapeutics News & Media
Eikon Therapeutics to Participate in Investor Conferences in September 2026
MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September:Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
MILLBRAE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today reported second quarter 2026 financial results and provided updates on its programs.Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
MILLBRAE, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial. This decision aligns with a recommendation from an independent DMC following a prespecified analysis of un
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eikon Therapeutics
Sign Up For FreeTo access detailed company insights
Eikon Therapeutics, founded in 2019, is a private biotechnology company headquartered in Hayward, California. Specializing in integrating advanced engineering with molecular and cell biology, Eikon aims to accelerate drug discovery and development.... Read More
